Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ImmuPharma PLC (DE:25I)
FRANKFURT:25I
ImmuPharma (25I) Stock Price & Analysis
0 Followers
25I Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.00 - €0.04
Previous Close€0.01
Volume0.00
Average Volume (3M)21.00K
Market Cap
€11.94M
Enterprise Value€11.17M
Total Cash (Recent Filing)£667.81K
Total Debt (Recent Filing)£111.00
Price to Earnings (P/E)N/A
Beta31.04
Next Earnings
May 23, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding333,403,115
10 Day Avg. Volume0
30 Day Avg. Volume21,000
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)6.28
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
25I FAQ
What was ImmuPharma PLC’s price range in the past 12 months?
ImmuPharma PLC lowest stock price was €0.00 and its highest was €0.04 in the past 12 months.
What is ImmuPharma PLC’s market cap?
Currently, no data Available
When is ImmuPharma PLC’s upcoming earnings report date?
ImmuPharma PLC’s upcoming earnings report date is May 23, 2024 which is in 37 days.
How were ImmuPharma PLC’s earnings last quarter?
ImmuPharma PLC released its earnings results on Aug 31, 2023. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.
Is ImmuPharma PLC overvalued?
According to Wall Street analysts ImmuPharma PLC’s price is currently Overvalued.
Does ImmuPharma PLC pay dividends?
ImmuPharma PLC does not currently pay dividends.
What is ImmuPharma PLC’s EPS estimate?
ImmuPharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuPharma PLC have?
Currently, no data Available
What happened to ImmuPharma PLC’s price movement after its last earnings report?
ImmuPharma PLC reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of ImmuPharma PLC?
Currently, no hedge funds are holding shares in DE:25I
---
ImmuPharma Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Company Description
ImmuPharma PLC
ImmuPharma PLC is a drug discovery and development company. The company is focused on the development of drugs based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. It has drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the company's drug candidate and is a treatment for lupus, and life-threatening autoimmune disease. The company's pipeline includes novel peptide-based therapeutics within four therapy areas: Autoimmunity; Anti-Infectives; Metabolism and Cancer.
---
Technical Analysis
---